Using Bispecific Antibodies to Target Saporin in T-Cell Leukaemia
Author Information
Author(s): D.J. Flavell, S. Cooper, B. Morland, R. French, S.U. Flavell
Primary Institution: University Department of Pathology, Southampton General Hospital
Hypothesis
Can bispecific antibodies effectively deliver saporin to T-cell leukaemia cell lines via CD7 and CD38?
Conclusion
Combining bispecific antibodies targeting CD7 and CD38 significantly increases the cytotoxicity of saporin in T-cell leukaemia cells.
Supporting Evidence
- The combination of both bispecific antibodies was ten times more effective than the best single antibody.
- Using both antibodies together resulted in a 4,000-fold increase in saporin toxicity.
- The CD38 antibody was highly effective, increasing saporin toxicity 80,000-fold against HPB-ALL cells.
Takeaway
This study shows that using two different antibodies together can make a cancer treatment much stronger and faster at killing cancer cells.
Methodology
The study used human T-ALL cell lines and measured protein synthesis inhibition through 3H-leucine uptake after exposure to bispecific antibodies and saporin.
Limitations
The study may not account for the heterogeneity of target antigen expression in tumor cells.
Want to read the original?
Access the complete publication on the publisher's website